Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2.

PMID:
20884247
2.

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.

Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.

Urology. 2004 Aug;64(2):317-22.

PMID:
15302487
3.

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.

Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Oncol Rep. 2012 Jan;27(1):3-9. doi: 10.3892/or.2011.1487. Epub 2011 Oct 4.

PMID:
21971890
4.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.

J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7.

5.

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O.

Cancer. 1995 Apr 15;75(8):2159-64.

6.

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.

Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Feb;74(3):225-34. doi: 10.1002/pros.22744. Epub 2013 Oct 16.

PMID:
24132762
7.

Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.

Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP.

Urology. 2001 Mar;57(3):471-5.

PMID:
11248622
10.

Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy.

Ismail A H, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG.

J Urol. 2002 Dec;168(6):2426-30.

PMID:
12441932
11.

Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.

Kaulsay KK, Ng EH, Ji CY, Ho GH, Aw TC, Lee KO.

Eur J Endocrinol. 1999 Feb;140(2):164-8.

12.

Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.

Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ.

J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):440-6.

PMID:
12218590
13.
14.

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.

Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, Fontana D, Angeli A.

Prostate. 2001 May 15;47(3):205-11.

PMID:
11351350
15.

The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery.

Cotterill AM, Mendel P, Holly JM, Timmins AG, Camacho-Hübner C, Hughes SC, Ross RM, Blum WF, Langford RM.

Clin Endocrinol (Oxf). 1996 Jan;44(1):91-101.

PMID:
8706300
16.

Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer.

Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE, Tricoli JV.

Urology. 2001 Oct;58(4):614-8.

PMID:
11597555
17.

Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):421-7.

18.

Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.

Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S.

Clin Adv Hematol Oncol. 2008 Jan;6(1):44-54.

PMID:
18322441
19.

Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E.

J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106.

20.

Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?

Lopez JB, Sahabudin RM, Chin LP.

Int J Biol Markers. 2004 Apr-Jun;19(2):164-7.

PMID:
15255551
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk